October 1 - 4, 2017
Wyndham Grand Pittsburgh
Abstract submission deadline: Monday, July 24
Advance registration deadline: Thursday, August 17
View Program PDF (as of 9/28/17)
Sunday, October 1
Monday, October 2
Tuesday, October 3
Wednesday, October 4
Sunday, October 1
Educational SessionSession Chairs: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts4:00 p.m.-6:00 p.m.
Ovarian cancer: From prevention and early detection to biology, biomarkers, heterogeneity, and immunologyAnil K. SoodRobert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, TexasKunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York
Treatment of ovarian cancer: Present and futureUrsula A. MatulonisRobert P. Edwards, University of Pittsburgh, Pittsburgh, Pennsylvania
Welcome Remarks / Opening Keynote Lecture6:15 p.m.-7:30 p.m.
Welcome RemarksRobert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas
Meeting the challenges in ovarian cancer Joan S. Brugge, Harvard Medical School, Boston, Massachusetts
Opening Reception7:30 p.m.-9:30 p.m.
Monday, October 2
Continental Breakfast / Networking Roundtables7:00 a.m.-8:00 a.m.
Plenary Session 1: DNA Damage and RepairSession Chairs: Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts, and Roger A. Greenberg, University of Pennsylvania, Philadelphia, Pennsylvania8:00 a.m.-10:00 a.m.
PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?Ursula A. Matulonis
Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cellLee Zou, Massachusetts General Hospital Cancer Center / Harvard Medical School, Boston, Massachusetts
Mitotic progression connects DNA damage to activation of anti-tumor immune responsesRoger A. Greenberg
Cyclin E: Targeting cell cycle dependencies in CCNE1 amplified tumors*Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition*Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, New York
Break10:00 a.m.-10:30 a.m.
Plenary Session 2: Metabolic Changes in Ovarian CancerSession Chairs: Ernst R. Lengyel, University of Chicago, Chicago, Illinois, and Ahmed A. Ahmed, University of Oxford, Oxford, England10:30 a.m.-12:30 p.m.
Discovery of IACS-10759, a novel oxidative phosphorylation inhibitor targeting critical cancer vulnerabilitiesGiulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, Texas
Stromal regulation of metastasisErnst R. Lengyel
Targeting micrometastasis for the treatment of ovarian cancerAhmed A. Ahmed
Kinase-mediated modulation of paclitaxel sensitivity in ovarian cancerZhen Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas
Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma*Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada
Free Time / Lunch on Own12:30 p.m.-3:00 p.m.
Plenary Session 3: Tumor MicroenvironmentSession Chairs: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Frances R. Balkwill, Barts Cancer Institute, London, England3:00 p.m.-5:00 p.m.
New directions in tumor microenvironmentAnil K. Sood
Deconstructing and reconstructing the ovarian cancer microenvironment
Frances R. Balkwill
Translating preclinical observations into trials addressing changes in the tumor microenvironmentRobert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas
Tumor-derived indoleamine 2,3- dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid derived suppressor cells in a murine model of ovarian cancer*Adaobi E. Amobi, Roswell Park Cancer Institute, Buffalo, New York
Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis*Mark A. Eckert, University of Chicago, Chicago, Illinois
Panel Discussion: Innovative Trial DesignSession Chair: Elise C. Kohn, CIB/CTEP/DCTD/NCI, Rockville, Maryland5:00 p.m.-6:00 p.m.
Panelists: Elise C. KohnMichael J. Birrer, UAB Comprehensive Cancer Center, Birmingham, Alabama
ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)*Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas
Poster Session A / Reception6:00 p.m.-8:30 p.m.
Top of page
Tuesday, October 3
Plenary Session 4: Drug Response and Resistance to TherapySession Chair: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia, and Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas8:00 a.m.-10:00 a.m.
Acquired chemotherapy resistance in high-grade serous ovarian cancer patientsDavid D. L. Bowtell
Systems approach to drug developmentGordon B. Mills
Exploiting synthetic lethality in the treatment of gynecological cancersChristopher Lord, Cancer Research UK London Research Institute, London, England
Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer*Claudia Iavarone, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts
Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer*Anniina Färkkilä, University of Helsinki, Helsinki, Finland
Plenary Session 5: Prevention and Early DetectionSession Chairs: Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas, and Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, Maryland10:30 a.m.-12:30 p.m.
Early detection of ovarian cancer: An updateRobert C. Bast, Jr.
PapGene, PapSEEK, and PapDREAming for early detection of ovarian cancerIe-Ming Shih
Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high grade serous ovarian cancerJames D. Brenton, University of Cambridge, Cambridge, England
Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq*Kevin M. Elias, Brigham and Women's Hospital, Boston, Massachusetts
Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study*Francesmary Modugno, University of Pittsburgh, Pittsburgh, Pennsylvania
Poster Session B / Lunch12:30 p.m.-3:00 p.m.
Plenary Session 6: Exploiting Vulnerabilities in Rare TumorsSession Chairs: David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, Texas, and David G. Huntsman, University of British Columbia, Vancouver, British Columbia, Canada3:00 p.m.-5:00 p.m.
Progress and future directions in the management of low-grade serous cancer of the ovaryDavid M. Gershenson
Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategiesDavid G. Huntsman
Therapeutic targeting ARID1A mutation in ovarian cancerRugang Zhang, The Wistar Institute, Philadelphia, Pennsylvania
Small cell carcinomas of the ovary: Strengths and weaknessesDouglas A. Levine, New York University, New York, New York
Panel Discussion: Funding Opportunities and Advocacy Groups5:00 p.m.-6:00 p.m.
Kiran Dhillon, Director of Scientific Programs, Rivkin Center for Ovarian Cancer Research, Seattle, WashingtonKathleen Gavin, Executive Director, Minnesota Ovarian Cancer Alliance, Minneapolis, MinnesotaKristin Parello-Plesner, Strategic Director, OvaCure, Copenhagen, DenmarkRunsi Sen, Founder, President & CEO, Ovarcome, Houston, TexasKatherine Taylor, Chief Executive, Ovarian Cancer Action, London, EnglandAnnie E. Ellis, Patient Advocate, Ovarian Cancer Research Fund Alliance, White Plains, New YorkSusan N. Perkins, Center for Cancer Training, National Cancer Institute, National Institutes of Health, Rockville, MarylandKaren Wylie, Science Officer, Ripple Effect, in support of The Congressionally Directed Medical Research Programs (CDMRP), Frederick, Maryland
Wednesday, October 4
Plenary Session 7: ImmunotherapySession Chairs: Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York, and David R. Spriggs, Memorial Sloan Kettering Cancer Center, New York, New York8:00 a.m.-10:00 a.m.
Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapyKunle Odunsi
How does the immune system contend with intratumoral heterogeneity in ovarian cancer?Brad Nelson, BC Cancer Agency, Vancouver Island, British Columbia, Canada
Translating fundamental immunobiology into adoptive T cell therapy for ovarian cancer Daniel J. Powell, University of Pennsylvania, Philadelphia, Pennsylvania
Strategies for glycosylation-based immunotargeting of MUC16David R. Spriggs
Epigenetic reprograming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T cell receptors*Li Shen, Roswell Park Cancer Institute, Buffalo, New York
Break10:00 a.m.-10:15 a.m.
Plenary Session 8: Genetics and Molecular DriversSession Chairs: Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania, and Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada10:15 a.m.-12:15 p.m.
Replication road blocks in Cyclin E-amplified ovarian cancersRonny I. Drapkin
Functional genetic architecture of serous ovarian cancerRobert K. Rottapel
Genomic rearrangement signatures in high grade serous ovarian cancersAndy Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas
TERT is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumors*Jessica A. Pilsworth, University of British Columbia, Vancouver, BC, Canada
CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high grade serous carcinoma*Josephine Walton, The University of Glasgow, Glasgow, United Kingdom
Closing Remarks / Departure12:15 p.m.
*Short talk from proffered abstract